Dr. Edwige Voisset completed her PhD at the Marseille Cancer Research Centre (CRCM) under the supervision of Paulo de Sepulveda in Patrice Dubreuil’s research group, focusing on the role of FES and FER kinases in both physiological and leukaemic signalling pathways downstream of the KIT and FLT3 tyrosine kinase receptors. Afterward, she moved to Cambridge for her first postdoctoral position, crossing the English Channel to join the MRC Cambridge Stem Cell Institute. There, she spent three years investigating the impact of p38alpha on the transformation potential of KRas-mutated bronchioalveolar stem cells. Following this valuable experience in oncology research, Edwige returned to the leukaemia field for her second postdoc, joining the late David Grimwade’s research group at King’s College London (KCL). Her work there centered on exploring the role of PML nuclear body disruption in the initiation and progression of acute promyelocytic leukaemia (APL). In 2019, she was awarded a Marie Skłodowska-Curie Fellowship (MSCA) by H2020, enabling her to return to the CRCM in Paulo de Sepulveda’s group, where she launched her own research project investigating the involvement of NPM1 and its mutants in DNA damage repair.
In September 2024, Edwige joined Vladimir Torbeev’s research group at the Strasbourg School of Engineering in Biotechnology (ESBS) – UMR 7242. In this pluridisciplinary environment, she continues her research on NPM1 biology, leveraging the team’s expertise in chemistry to advance her work.